CPDC is a not-for-profit corporation founded in 2008 to advance probe (chemical agents that will carry medical isotopes to targets in the body) discovery, development, and clinical research, and provide a reliable supply of radiopharmaceuticals. CPDC’s mission is to improve the quality of Canadian patients' lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 15 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s self-funding business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through collaboration with partners including industry, academia and government.